Q-omics provides the consensus-scored CDRT15P12 profile across patient tissues and cancer cell-line models. CDRT15P12 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, CDRT15P12 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, CDRT15P12 RNA expression shows 8,931 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUSC, and ACC as cancer lineages where CDRT15P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDRT15P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDRT15P12 survival associations across molecular data types. CDRT15P12 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDRT15P12 RNA expression–survival associations across cancer types. High CDRT15P12 expression shows unfavorable associations in KIRC, but favorable associations in LUSC, BRCA, HNSC, OV and LGG. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify LUSC as the clearest survival context for CDRT15P12 RNA expression.
This table summarizes CDRT15P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CDRT15P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDRT15P12 shows lower tumor expression in HNSC, THCA and BRCA and higher tumor expression in LUSC, LUAD and BLCA. The LUSC box plot shows higher CDRT15P12 RNA expression in tumor versus normal tissue (log2 FC = +0.935, t-test p < 0.001).
This table shows molecular features associated with CDRT15P12 in patient tissues and cancer cell lines. In patient samples, CDRT15P12 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
